US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NeOnc Technologies Holdings

4.68

+0.11502.52%

Post-market: 4.700.0250+0.53%19:30 EDT

Volume:167.74K

Turnover:765.25K

Market Cap:121.61M

PE:-2.57

High:4.89

Open:4.61

Low:4.39

Close:4.56

52wk High:12.99

52wk Low:3.01

Shares:26.01M

Float Shares:8.83M

Volume Ratio:0.43

T/O Rate:1.90%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8200

EPS(LYR):-3.2036

ROE:--

ROA:-634.99%

PB:-5.61

PE(LYR):-1.46

Loading ...

Overview Company News Filings

Neonc Wins UAE IND Authorization for Neo100 in Recurrent High-grade Glioma

NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum

Neonc Technologies Receives UAE Ind Approval for Neo100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

THOMSON REUTERS

Neonc Technologies - Top-Line Data From Neo100-01 Phase 2a Trial Expected by End of July 2026

THOMSON REUTERS

NeOnc says Abu Dhabi health regulator grants IND status for NEO100 glioma trials

NeOnc gains Abu Dhabi IND clearance for brain cancer drug candidate NEO212

NeOnc Technologies Says Abu Dhabi Clears NEO212 for Phase 2 Brain Cancer Trial

MT Newswires Live

Neonc Technologies - Receives Ind Clearance for Neo212 From Department of Health Abu Dhabi

THOMSON REUTERS

Neonc Technologies - Doh Clearance for Neo212 Does Not Constitute Marketing Authorization

THOMSON REUTERS

NeOnc wins UAE IND clearance for brain cancer drug NEO212

NeOnc Technologies files to sell 555,554 shares of common stock for holders

NeOnc Technologies enters agreement for up to $5 million Series A convertible preferred private placement

Neonc Technologies - to Issue up to $5 Mln Series a Convertible Preferred Stock in Private Placement - SEC Filing

THOMSON REUTERS

NeOnc Technologies announces private placement of up to $5 million Series A convertible preferred stock

NeOnc Technologies announces annual shareholder meeting notice

The Next Great AI Revolution May Be Drug Delivery

NeOnc Technologies Price Target Maintained With a $15.00/Share by BTIG

Maxim Group, Alliance Global, BTIG initiate coverage of NeOnc Technologies

NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones

NeOnc Technologies Initiated at Buy by Maxim Group

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/NTHI/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NTHI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":4.675,"timestamp":1787342400000,"preClose":4.56,"halted":0,"volume":167735,"hourTrading":{"tag":"盘后","latestPrice":4.7,"preClose":4.675,"latestTime":"19:30 EDT","volume":248,"amount":1171.535,"timestamp":1787355007389,"change":0.025,"changeRate":0.005348,"amplitude":0.005348},"delay":0,"changeRate":0.025219298245614086,"floatShares":8832900,"shares":26013100,"eps":-1.82,"marketStatus":"Market Closed","change":0.115,"latestTime":"08-21 16:00:00 EDT","open":4.61,"high":4.8899,"low":4.39,"amount":765249.842425,"amplitude":0.109627,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.82,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":4.56,"preHourTrading":{"tag":"盘前","latestPrice":4.74,"preClose":4.56,"latestTime":"09:02 EDT","volume":1497,"amount":7123.2598302,"timestamp":1787317341481,"change":0.18,"changeRate":0.039474,"amplitude":0.035088},"postHourTrading":{"tag":"盘后","latestPrice":4.7,"preClose":4.675,"latestTime":"19:30 EDT","volume":248,"amount":1171.535,"timestamp":1787355007389,"change":0.025,"changeRate":0.005348,"amplitude":0.005348},"volumeRatio":0.431495534033352},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","floatShares":8832900,"roa":"-634.99%","roe":"--","lyrEps":-3.203615,"volumeRatio":0.431495534033352,"shares":26013100,"dividePrice":0,"high":4.8899,"amplitude":0.109627,"preClose":4.56,"low":4.39,"week52Low":3.005,"pbRate":"-5.61","psRate":"3041.04","week52High":12.99,"institutionHeld":0,"latestPrice":4.675,"eps":-1.82,"divideRate":0,"volume":167735,"delay":0,"ttmEps":-1.82,"open":4.61,"prevYearClose":8.27,"prevWeekClose":4.22,"prevMonthClose":3.49,"prevQuarterClose":4.53,"fiveDayClose":4.22,"twentyDayClose":3.43,"sixtyDayClose":4.835},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTHI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-10","symbol":"NTHI","fiscalQuarterEnding":"2026/06","expectedEps":-0.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786334400000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2026-05-15","symbol":"NTHI","fiscalQuarterEnding":"2026/03","expectedEps":-0.3,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.38},{"market":"US","date":"2026-03-31","symbol":"NTHI","fiscalQuarterEnding":"2025/12","expectedEps":-0.37,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-0.72},{"market":"US","date":"2025-11-14","symbol":"NTHI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-18","symbol":"NTHI","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1755489600000,"reportTimeType":"","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTHI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NTHI\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1779249600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NTHI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NTHI","date":"2026-08-21","current":-2.568681,"percent":0.730114,"low":-26.074295,"twenty":-4.279913,"median":-3.15078,"eighty":-2.244708,"high":-1.357276,"avg":-4.016425,"sd":3.277514,"marketCap":113347108},"quantilePoints":[{"date":"2024-03-28","current":-18.899455,"twenty":-18.899455,"median":-18.899455,"eighty":-18.899455,"marketCap":282000000},{"date":"2025-03-28","current":-18.905834,"twenty":-19.009816,"median":-18.905834,"eighty":-18.902007,"marketCap":224950380},{"date":"2025-04-04","current":-15.093157,"twenty":-20.260752,"median":-18.902645,"eighty":-16.151884,"marketCap":179585386},{"date":"2025-04-11","current":-14.179375,"twenty":-19.504518,"median":-17.739974,"eighty":-15.124667,"marketCap":168712785},{"date":"2025-04-17","current":-11.028403,"twenty":-19.044476,"median":-15.392499,"eighty":-12.855967,"marketCap":131221055},{"date":"2025-04-25","current":-9.437162,"twenty":-18.904558,"median":-14.667776,"eighty":-10.965384,"marketCap":112287731},{"date":"2025-05-02","current":-8.444606,"twenty":-18.667559,"median":-12.525115,"eighty":-9.437162,"marketCap":100477836},{"date":"2025-05-09","current":-10.398208,"twenty":-17.342951,"median":-11.028403,"eighty":-9.33318,"marketCap":123722709},{"date":"2025-05-16","current":-2.933338,"twenty":-15.682389,"median":-10.398208,"eighty":-8.444606,"marketCap":137753858},{"date":"2025-05-23","current":-2.969802,"twenty":-15.348385,"median":-9.44504,"eighty":-3.015179,"marketCap":139466268},{"date":"2025-05-30","current":-2.99006,"twenty":-15.171931,"median":-9.437162,"eighty":-2.969802,"marketCap":140417606},{"date":"2025-06-06","current":-3.034627,"twenty":-15.093157,"median":-9.311123,"eighty":-2.969802,"marketCap":142510552},{"date":"2025-06-13","current":-2.593006,"twenty":-14.242395,"median":-8.476116,"eighty":-2.937389,"marketCap":121771366},{"date":"2025-06-20","current":-1.928548,"twenty":-14.191979,"median":-7.853798,"eighty":-2.929004,"marketCap":90567453},{"date":"2025-06-27","current":-1.616577,"twenty":-12.855967,"median":-3.034627,"eighty":-2.802066,"marketCap":75916836},{"date":"2025-07-03","current":-2.362066,"twenty":-12.222621,"median":-3.010317,"eighty":-2.532985,"marketCap":110926104},{"date":"2025-07-11","current":-1.977167,"twenty":-11.425425,"median":-2.998163,"eighty":-2.362066,"marketCap":92850666},{"date":"2025-07-18","current":-1.786743,"twenty":-11.028403,"median":-2.99006,"eighty":-2.222692,"marketCap":83908082},{"date":"2025-07-25","current":-1.904238,"twenty":-10.981139,"median":-2.959854,"eighty":-1.949616,"marketCap":89425847},{"date":"2025-08-01","current":-1.98527,"twenty":-10.618776,"median":-2.937389,"eighty":-1.970684,"marketCap":93231202},{"date":"2025-08-08","current":-1.944754,"twenty":-10.133526,"median":-2.931642,"eighty":-1.939892,"marketCap":91328524},{"date":"2025-08-15","current":-2.102765,"twenty":-9.654579,"median":-2.909028,"eighty":-1.943134,"marketCap":98748967},{"date":"2025-08-22","current":-2.604584,"twenty":-9.443464,"median":-2.799635,"eighty":-1.954478,"marketCap":110548110},{"date":"2025-08-29","current":-3.15078,"twenty":-9.437162,"median":-2.795584,"eighty":-1.970684,"marketCap":133730643},{"date":"2025-09-05","current":-3.371966,"twenty":-9.437162,"median":-2.876616,"eighty":-1.980408,"marketCap":143118611},{"date":"2025-09-12","current":-4.405675,"twenty":-9.43086,"median":-2.918386,"eighty":-1.98527,"marketCap":186992991},{"date":"2025-09-19","current":-5.457439,"twenty":-9.377293,"median":-2.933338,"eighty":-1.993373,"marketCap":231633736},{"date":"2025-09-26","current":-4.681029,"twenty":-9.292217,"median":-2.939656,"eighty":-2.005528,"marketCap":198680053},{"date":"2025-10-03","current":-5.141458,"twenty":-8.961365,"median":-2.969802,"eighty":-2.008769,"marketCap":218222354},{"date":"2025-10-10","current":-5.407785,"twenty":-8.482417,"median":-2.99006,"eighty":-2.016872,"marketCap":229526233},{"date":"2025-10-17","current":-4.730683,"twenty":-8.444606,"median":-3.002214,"eighty":-2.039561,"marketCap":200787556},{"date":"2025-10-24","current":-3.769199,"twenty":-7.97196,"median":-3.022472,"eighty":-2.067922,"marketCap":159978635},{"date":"2025-10-31","current":-4.590749,"twenty":-7.105442,"median":-3.15078,"eighty":-2.071973,"marketCap":194848230},{"date":"2025-11-07","current":-4.446301,"twenty":-6.304447,"median":-3.298614,"eighty":-2.085748,"marketCap":188717312},{"date":"2025-11-14","current":-4.053582,"twenty":-5.457439,"median":-3.638293,"eighty":-2.120592,"marketCap":172048879},{"date":"2025-11-21","current":-2.32457,"twenty":-5.457439,"median":-3.482559,"eighty":-2.150574,"marketCap":113613569},{"date":"2025-11-28","current":-3.566132,"twenty":-5.449314,"median":-3.447134,"eighty":-2.162729,"marketCap":174295011},{"date":"2025-12-05","current":-3.725512,"twenty":-5.41591,"median":-3.522302,"eighty":-2.193521,"marketCap":182084733},{"date":"2025-12-12","current":-3.733481,"twenty":-5.411396,"median":-3.568124,"eighty":-2.214589,"marketCap":182474219},{"date":"2025-12-19","current":-2.797122,"twenty":-5.405979,"median":-3.570116,"eighty":-2.278603,"marketCap":136709607},{"date":"2025-12-26","current":-3.327062,"twenty":-5.398757,"median":-3.566132,"eighty":-2.301292,"marketCap":162610430},{"date":"2026-01-02","current":-3.295186,"twenty":-5.391535,"median":-3.474488,"eighty":-2.319914,"marketCap":161052485},{"date":"2026-01-09","current":-3.916768,"twenty":-5.368062,"median":-3.548202,"eighty":-2.33285,"marketCap":191432398},{"date":"2026-01-16","current":-3.466519,"twenty":-5.344589,"median":-3.566132,"eighty":-2.344813,"marketCap":169426436},{"date":"2026-01-23","current":-3.486442,"twenty":-5.296741,"median":-3.53824,"eighty":-2.348861,"marketCap":170400151},{"date":"2026-01-30","current":-3.486442,"twenty":-5.229933,"median":-3.552186,"eighty":-2.357204,"marketCap":170400151},{"date":"2026-02-06","current":-3.681683,"twenty":-5.174862,"median":-3.566132,"eighty":-2.362066,"marketCap":179942559},{"date":"2026-02-13","current":-4.169784,"twenty":-5.146875,"median":-3.570116,"eighty":-2.389761,"marketCap":203798580},{"date":"2026-02-20","current":-3.426674,"twenty":-5.12611,"median":-3.574101,"eighty":-2.410019,"marketCap":167479005},{"date":"2026-02-27","current":-4.020365,"twenty":-5.049824,"median":-3.613946,"eighty":-2.417236,"marketCap":196495717},{"date":"2026-03-06","current":-3.835101,"twenty":-4.966315,"median":-3.638073,"eighty":-2.428412,"marketCap":187440892},{"date":"2026-03-13","current":-3.660224,"twenty":-4.933814,"median":-3.653791,"eighty":-2.438178,"marketCap":178893747},{"date":"2026-03-20","current":-3.253532,"twenty":-4.851659,"median":-3.642057,"eighty":-2.502974,"marketCap":159016664},{"date":"2026-03-27","current":-2.981402,"twenty":-4.767698,"median":-3.621915,"eighty":-2.597637,"marketCap":145716276},{"date":"2026-04-02","current":-1.961459,"twenty":-4.735197,"median":-3.603287,"eighty":-2.595322,"marketCap":121897269},{"date":"2026-04-10","current":-1.961307,"twenty":-4.734294,"median":-3.574101,"eighty":-2.414974,"marketCap":121887825},{"date":"2026-04-17","current":-2.012281,"twenty":-4.720752,"median":-3.566132,"eighty":-2.352342,"marketCap":125055639},{"date":"2026-04-24","current":-1.920085,"twenty":-4.679223,"median":-3.562148,"eighty":-2.305948,"marketCap":119325998},{"date":"2026-05-01","current":-1.771769,"twenty":-4.657556,"median":-3.53824,"eighty":-2.205893,"marketCap":110108750},{"date":"2026-05-08","current":-2.630543,"twenty":-4.597971,"median":-3.502161,"eighty":-2.162729,"marketCap":163478290},{"date":"2026-05-15","current":-2.213061,"twenty":-4.588041,"median":-3.478473,"eighty":-2.19289,"marketCap":137533354},{"date":"2026-05-22","current":-3.511755,"twenty":-4.577207,"median":-3.486442,"eighty":-2.19724,"marketCap":135694649},{"date":"2026-05-29","current":-3.138303,"twenty":-4.577207,"median":-3.483777,"eighty":-2.19881,"marketCap":121264435},{"date":"2026-06-05","current":-2.990888,"twenty":-4.568179,"median":-3.474488,"eighty":-2.200003,"marketCap":115568297},{"date":"2026-06-12","current":-2.948302,"twenty":-4.559151,"median":-3.434643,"eighty":-2.209008,"marketCap":113922747},{"date":"2026-06-18","current":-3.151407,"twenty":-4.512205,"median":-3.406752,"eighty":-2.21225,"marketCap":121770758},{"date":"2026-06-26","current":-2.954853,"twenty":-4.486024,"median":-3.393823,"eighty":-2.226031,"marketCap":114175908},{"date":"2026-07-02","current":-2.922095,"twenty":-4.474288,"median":-3.367616,"eighty":-2.229383,"marketCap":112910100},{"date":"2026-07-10","current":-3.013469,"twenty":-4.460746,"median":-3.339093,"eighty":-2.231778,"marketCap":116440808},{"date":"2026-07-17","current":-2.181241,"twenty":-4.449912,"median":-3.327062,"eighty":-2.231778,"marketCap":84283436},{"date":"2026-07-24","current":-2.436279,"twenty":-4.432759,"median":-3.283232,"eighty":-2.231778,"marketCap":94138114},{"date":"2026-07-31","current":-2.342317,"twenty":-4.416509,"median":-3.25181,"eighty":-2.244708,"marketCap":90507443},{"date":"2026-08-07","current":-2.349029,"twenty":-4.389966,"median":-3.211511,"eighty":-2.26624,"marketCap":90766777},{"date":"2026-08-14","current":-1.763689,"twenty":-4.333179,"median":-3.181853,"eighty":-2.231004,"marketCap":83246101},{"date":"2026-08-21","current":-2.401422,"twenty":-4.279913,"median":-3.15078,"eighty":-2.244708,"marketCap":113347108}],"updateTime":1787511364438},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTHI\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645813583","title":"Neonc Wins UAE IND Authorization for Neo100 in Recurrent High-grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2645813583","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645813583?lang=en_us&edition=fundamental","pubTime":"2026-06-24 20:45","pubTimestamp":1782305119,"startTime":"0","endTime":"0","summary":"NeOnc wins UAE IND authorization for NEO100 in recurrent high-grade gliomaNeOnc Technologies secured a second UAE Investigational New Drug authorization for NEO100, its intranasal therapy candidate fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL3qkvnC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","IE00BKPKM429.USD","IE00BN0W2W23.USD","NTHI","SG9999014005.SGD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210149790.SGD","BK4007","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645813606","title":"NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2645813606","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645813606?lang=en_us&edition=fundamental","pubTime":"2026-06-24 20:45","pubTimestamp":1782305100,"startTime":"0","endTime":"0","summary":"NTHI Continues to Build Regulatory Momentum prior to Upcoming Phase 2 DataDENVER, June  24, 2026  (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is entering one ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/24/3316856/0/en/NeOnc-Ignites-Explosive-Summer-4-New-Research-Reports-UAE-Dubai-Drug-Approval-Fuel-Breakout-Momentum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4007","NTHI","UAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645839477","title":"Neonc Technologies Receives UAE Ind Approval for Neo100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2645839477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645839477?lang=en_us&edition=fundamental","pubTime":"2026-06-23 21:01","pubTimestamp":1782219713,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42V0XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645839298","title":"Neonc Technologies - Top-Line Data From Neo100-01 Phase 2a Trial Expected by End of July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645839298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645839298?lang=en_us&edition=fundamental","pubTime":"2026-06-23 21:01","pubTimestamp":1782219713,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42V0XF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645839231","title":"NeOnc says Abu Dhabi health regulator grants IND status for NEO100 glioma trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2645839231","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645839231?lang=en_us&edition=fundamental","pubTime":"2026-06-23 21:01","pubTimestamp":1782219673,"startTime":"0","endTime":"0","summary":"NeOnc Technologies won UAE IND clearance from Abu Dhabi’s Department of Health for NEO100 in recurrent Grade III-IV gliomas.Authorization supports adult trials through Phase 2, with a pediatric pathway under further protocol review.Top-line data from the fully enrolled NEO100-01 Phase 2a study are expected by end-July 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL1Lx44s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014039.USD","BK4585","LU2210149790.SGD","IE00BN0W2V16.EUR","BK4112","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2095319765.USD","NDAQ","SG9999014005.SGD","NTHI","IE00BGHQF748.EUR","LU2210150020.SGD","BK4007","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022729","title":"NeOnc gains Abu Dhabi IND clearance for brain cancer drug candidate NEO212","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022729","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022729?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:46","pubTimestamp":1782132404,"startTime":"0","endTime":"0","summary":"NeOnc Technologies secured Department of Health – Abu Dhabi IND authorization for NEO212, opening an additional clinical development pathway for glioblastoma.The oral perillyl alcohol–temozolomide conjugate has completed Phase 1 dose escalation; 610 mg was selected as the recommended Phase 2 dose.The company plans a Type B end-of-Phase 1 meeting with the FDA to discuss next steps and potential registrational pathways.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL64VKM8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643768937","title":"NeOnc Technologies Says Abu Dhabi Clears NEO212 for Phase 2 Brain Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643768937","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643768937?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:52","pubTimestamp":1781617928,"startTime":"0","endTime":"0","summary":"NeOnc Technologies  said Tuesday it has received investigational new drug clearance from the Abu Dhabi's Department of Health for its brain tumor treatment NEO212, enabling phase 2 evaluation of the therapy in the UAE.The authorization marks the first international regulatory clearance for NEO212 following completion of phase 1 clinical evaluation and represents a \"significant step\" toward expanding the program into multiple global markets, the company said.The clearance also adds an international clinical pathway for NEO212 while discussions continue with the US Food and Drug Administration on a potential registrational pathway for the therapy, the company said.Shares of NeOnc Technologies were 6% higher in Tuesday trading.Price: 4.39, Change: -0.12, Percent Change: -2.66","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643750847","title":"Neonc Technologies - Receives Ind Clearance for Neo212 From Department of Health Abu Dhabi","url":"https://stock-news.laohu8.com/highlight/detail?id=2643750847","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643750847?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:06","pubTimestamp":1781615163,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42O0D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643750840","title":"Neonc Technologies - Doh Clearance for Neo212 Does Not Constitute Marketing Authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=2643750840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643750840?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:06","pubTimestamp":1781615163,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42O0D4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643275771","title":"NeOnc wins UAE IND clearance for brain cancer drug NEO212","url":"https://stock-news.laohu8.com/highlight/detail?id=2643275771","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643275771?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:01","pubTimestamp":1781614864,"startTime":"0","endTime":"0","summary":"NeOnc Technologies won UAE IND clearance from the Department of Health – Abu Dhabi for NEO212, enabling Phase 2 clinical evaluation.The oral perillyl alcohol–temozolomide conjugate recently completed Phase 1 dose escalation, setting a 610 mg recommended Phase 2 dose.The approval adds an international clinical pathway alongside ongoing U.S. FDA talks on a potential registrational strategy for NEO212.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL1fY0ty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4112","SG9999014039.USD","BK4007","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD","SG9999014005.SGD","NDAQ","NTHI","IE00BN0W2V16.EUR","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","LU0314104364.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643786535","title":"NeOnc Technologies files to sell 555,554 shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2643786535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643786535?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:31","pubTimestamp":1781555483,"startTime":"0","endTime":"0","summary":"16:25 EDT NeOnc Technologies (NTHI) files to sell 555,554 shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neonc-technologies-files-to-sell-555554-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neonc-technologies-files-to-sell-555554-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643055642","title":"NeOnc Technologies enters agreement for up to $5 million Series A convertible preferred private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2643055642","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643055642?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:36","pubTimestamp":1781526984,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings announced a Securities Purchase Agreement with accredited investors for up to $5 million of Series A Convertible Preferred Stock.Terms include issuer redemption rights, a 4.99% beneficial ownership cap with an optional increase to 9.99%, and a $1 conversion floor price.Proceeds are expected to support corporate initiatives and provide financial flexibility ahead of anticipated Phase 2 clinical updates for NEO100 and NEO212.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDLLmLG5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642264371","title":"Neonc Technologies - to Issue up to $5 Mln Series a Convertible Preferred Stock in Private Placement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2642264371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642264371?lang=en_us&edition=fundamental","pubTime":"2026-06-12 18:04","pubTimestamp":1781258684,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42K06S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642264307","title":"NeOnc Technologies announces private placement of up to $5 million Series A convertible preferred stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2642264307","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642264307?lang=en_us&edition=fundamental","pubTime":"2026-06-12 18:04","pubTimestamp":1781258665,"startTime":"0","endTime":"0","summary":"NeOnc Technologies entered a private placement to sell up to USD 5 million of Series A Convertible Preferred Stock to accredited investors.Series A Preferred priced at USD 833.34 per share; up to 6,000 shares authorized; stated value USD 1,000 per share.Sale is unregistered under the Securities Act; relies on Section 4 exemption and Rule 506 of Regulation D.Closing is subject to customary conditions, including receipt of investor funds and issuance of the securities.Company agreed to file a resale registration statement for common shares issuable on conversion within specified timeframes after triggering events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to genera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL3XZDKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642923173","title":"NeOnc Technologies announces annual shareholder meeting notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2642923173","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642923173?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:16","pubTimestamp":1781208996,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings will hold its annual shareholder meeting in a virtual format on Aug. 14, 2026.Shareholders will vote to elect two Class I directors for three-year terms ending at the 2029 annual meeting.Vote set on amending the 2023 Equity Incentive Plan, including adding 1,000,000 shares for awards.Proposal also adds annual plan share increases from 2027 through 2033 equal to 20% of shares outstanding at prior year-end.Other items include ratifying CBIZ CPAs as auditor for the year ending Dec. 31, 2026, and authorizing meeting adjournment if needed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data G","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL8ZlVj8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639620441","title":"The Next Great AI Revolution May Be Drug Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2639620441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639620441?lang=en_us&edition=fundamental","pubTime":"2026-05-29 21:05","pubTimestamp":1780059900,"startTime":"0","endTime":"0","summary":"DENVER, May  29, 2026  (GLOBE NEWSWIRE) -- (www.247marketnews.com) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/29/3303632/0/en/The-Next-Great-AI-Revolution-May-Be-Drug-Delivery.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","ARTY","NTHI","BK4587","BK4023","CHAT","AIYY","AI","BK4585","AGIX","BK4551","BK4007","BK4528","AIPO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638515940","title":"NeOnc Technologies Price Target Maintained With a $15.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2638515940","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638515940?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:36","pubTimestamp":1779791760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NTHI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 26, 2026 06:36 ET (10:36 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636761852","title":"Maxim Group, Alliance Global, BTIG initiate coverage of NeOnc Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2636761852","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636761852?lang=en_us&edition=fundamental","pubTime":"2026-05-19 22:28","pubTimestamp":1779200913,"startTime":"0","endTime":"0","summary":"Maxim Group initiated coverage of NeOnc Technologies with a favorable rating and price target.Alliance Global Partners also started coverage with a favorable rating and target.BTIG Research launched coverage with an advantageous rating and target, adding to rising analyst attention ahead of expected interim Phase 2a data for lead candidate NEO100.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL4xtBp7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","BK4585","IE00BN0W2W23.USD","BK4588","NTHI","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","BK4007","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636185756","title":"NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2636185756","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636185756?lang=en_us&edition=fundamental","pubTime":"2026-05-19 22:28","pubTimestamp":1779200880,"startTime":"0","endTime":"0","summary":"Alliance Global Partners and Maxim Group Initiate Separate NeOnc Technologies Coverage with Favorable RatingsDENVER, May  19, 2026  (GLOBE NEWSWIRE) -- (www.247marketnews.com) – NeOnc Technologies (NA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297723/0/en/NeOnc-Technologies-Gains-Growing-Institutional-Support-Ahead-of-Key-Brain-Cancer-Clinical-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007","BK4135","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636005908","title":"NeOnc Technologies Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2636005908","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636005908?lang=en_us&edition=fundamental","pubTime":"2026-05-19 03:07","pubTimestamp":1779131220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NTHI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 18, 2026 15:07 ET (19:07 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":107,"code":"91000000","status":"200"}]}}